Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 16,549 shares of the firm’s stock in a transaction dated Monday, January 15th. The stock was sold at an average price of $51.76, for a total value of $856,576.24. Following the completion of the transaction, the chairman now directly owns 67,626 shares in the company, valued at $3,500,321.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Ionis Pharmaceuticals Inc (NASDAQ:IONS) opened at $51.61 on Thursday. Ionis Pharmaceuticals Inc has a 12-month low of $37.26 and a 12-month high of $65.51. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25. The firm has a market capitalization of $6,420.00, a PE ratio of 368.64 and a beta of 2.86.
Several research analysts have issued reports on the company. Morgan Stanley raised their target price on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 8th. Barclays dropped their target price on Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a research report on Thursday, September 21st. BMO Capital Markets raised their target price on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. BidaskClub cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 22nd. Finally, Zacks Investment Research cut Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $50.76.
TRADEMARK VIOLATION WARNING: This article was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3143953/ionis-pharmaceuticals-inc-ions-chairman-stanley-t-crooke-sells-16549-shares.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.